On-Demand Webinar: Reach the Clinic Faster: Integrated Biopharmaceutics & Drug Substance Strategies

Learn how choosing an integrated service provider can help to accelerate your drug development timeline.

Drug developers face many challenges and considerations in the preclinical and candidate development stage. They start with selecting the right molecule to take forward into clinical development and understanding the best drug substance and drug product development strategy to reach the clinic. 

To simplify and expedite this phase, developers can leverage an integrated biopharmaceutics, drug substance, and drug product development strategy to make science-led, data-driven decisions that greatly improve formulation performance and streamline the outsourcing process. 

The tight integration of these key activities under a single organization improves the supply chain by removing them from the critical path and allows for a seamless transition into clinical research with "clinic ready" deliverables.

Hear the benefits of integrating biopharmaceutics and drug substance activities in order to accelerate timelines to first-in-human studies, minimize risks, and improve the likelihood of downstream success from our experts. 

Moderated by Dr. Asma Patel, VP of Integrated Development Services at Quotient Sciences, panelists include Dr. Richard Castledine, Dr. Steve Byard, and Dr. Eleanor Row, Executive Director of Candidate Development.